• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

作者信息

Evans Marc, Dejager Sylvie, Schweizer Anja, Foley James E

机构信息

University Hospital Llandough, Cardiff, UK,

出版信息

Diabetes Ther. 2015 Mar;6(1):1-5. doi: 10.1007/s13300-015-0104-4. Epub 2015 Mar 18.

DOI:10.1007/s13300-015-0104-4
PMID:25783754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4374076/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccec/4374076/bf87d2ed5439/13300_2015_104_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccec/4374076/bf87d2ed5439/13300_2015_104_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccec/4374076/bf87d2ed5439/13300_2015_104_Fig1_HTML.jpg

相似文献

1
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?在治疗2型糖尿病合并慢性肾脏病导致肾小球滤过率降低的患者时，二肽基肽酶-4抑制剂之间是否存在安全性差异的证据？
Diabetes Ther. 2015 Mar;6(1):1-5. doi: 10.1007/s13300-015-0104-4. Epub 2015 Mar 18.
2
Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.二肽基肽酶4抑制剂在老年2型糖尿病管理中的有效性和安全性：一项系统评价及减少不适当处方的建议制定
BMC Geriatr. 2017 Oct 16;17(Suppl 1):226. doi: 10.1186/s12877-017-0571-8.
3
Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus.可溶性二肽基肽酶-4 水平与 2 型糖尿病患者肾功能下降有关。
Diabetes Metab J. 2019 Feb;43(1):97-104. doi: 10.4093/dmj.2018.0030. Epub 2018 Oct 8.
4
Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.二肽基肽酶-4抑制剂对2型糖尿病患者的肾脏保护作用：一项队列研究
J Diabetes Res. 2016;2016:1423191. doi: 10.1155/2016/1423191. Epub 2016 Dec 29.
5
The kidney and cardiovascular outcome trials.肾脏和心血管结局试验。
J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616.
6
Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.在泰国，二肽基肽酶-4抑制剂单药治疗与磺脲类单药治疗对2型糖尿病合并慢性肾脏病患者的成本效益分析
J Med Econ. 2017 Feb;20(2):171-181. doi: 10.1080/13696998.2016.1238386. Epub 2016 Sep 29.
7
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.口服抗糖尿病药物的安全性和疗效更新：DPP-4 抑制剂和 SGLT-2 抑制剂。
Expert Opin Drug Saf. 2019 Aug;18(8):691-701. doi: 10.1080/14740338.2019.1626823. Epub 2019 Jun 7.
8
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.二肽基肽酶-4 抑制剂对 2 型糖尿病患者肾脏结局的影响：系统评价和荟萃分析。
Endocrinol Metab (Seoul). 2019 Mar;34(1):80-92. doi: 10.3803/EnM.2019.34.1.80.
9
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials.探讨 DPP-4 抑制剂在肾脏方面的作用：从实验室到临床试验。
Pharmacol Res. 2018 Mar;129:274-294. doi: 10.1016/j.phrs.2017.12.001. Epub 2017 Dec 6.
10
Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting.回顾性数据库分析：评估在基层医疗环境中，2型糖尿病（T2DM）患者从其他二肽基肽酶-4（DPP-4）抑制剂治疗转换为阿格列汀治疗的临床结局。
Diabetes Ther. 2019 Aug;10(4):1499-1507. doi: 10.1007/s13300-019-0662-y. Epub 2019 Jul 1.

引用本文的文献

1
Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance.维格列汀的临床安全性与耐受性——来自随机试验、观察性研究及上市后监测的见解
Eur Endocrinol. 2017 Aug;13(2):68-72. doi: 10.17925/EE.2017.13.02.68. Epub 2017 Aug 22.
2
Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin.接受单药替奈利汀降糖治疗的血液透析患者发生低血糖昏迷
Clin Med Insights Case Rep. 2018 Mar 20;11:1179547618763358. doi: 10.1177/1179547618763358. eCollection 2018.

本文引用的文献

1
Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.基于肠促胰岛素的疗法在慢性肾脏病合并2型糖尿病患者中的药代动力学及临床应用
Clin Pharmacokinet. 2015 Jan;54(1):1-21. doi: 10.1007/s40262-014-0198-2.
2
Metformin and other antidiabetic agents in renal failure patients.在肾功能衰竭患者中使用二甲双胍和其他抗糖尿病药物。
Kidney Int. 2015 Feb;87(2):308-22. doi: 10.1038/ki.2014.19. Epub 2014 Mar 5.
3
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
维格列汀与胰岛素联合使用效果的临床证据及作用机制基础。
Vasc Health Risk Manag. 2013;9:57-64. doi: 10.2147/VHRM.S40972. Epub 2013 Feb 15.
4
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.KDIGO 临床实践指南：糖尿病与慢性肾脏病（2012 年更新版）
Am J Kidney Dis. 2012 Nov;60(5):850-86. doi: 10.1053/j.ajkd.2012.07.005.
5
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.在伴有严重肾功能损害的 2 型糖尿病患者中，利拉利汀的长期疗效和安全性：一项为期 1 年、随机、双盲、安慰剂对照研究。
Diabetes Care. 2013 Feb;36(2):237-44. doi: 10.2337/dc12-0706. Epub 2012 Oct 1.
6
Linagliptin: a review of its use in the management of type 2 diabetes mellitus.利拉鲁肽：在 2 型糖尿病管理中的应用评价。
Drugs. 2012 Sep 10;72(13):1793-824. doi: 10.2165/11209570-000000000-00000.
7
Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.肠促胰岛素疗法在2型糖尿病合并肾功能损害患者管理中的应用
Hosp Pract (1995). 2012 Apr;40(2):7-21. doi: 10.3810/hp.2012.04.965.
8
The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.二肽基肽酶-4（DPP-4）抑制剂维格列汀可改善血液透析的 2 型糖尿病患者的血糖控制。
Endocr J. 2011;58(11):979-87. doi: 10.1507/endocrj.ej11-0025. Epub 2011 Sep 15.
9
Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment.大型门诊电子病历数据库中 2 型糖尿病和肾功能损害：诊断率和抗高血糖药物剂量调整。
Postgrad Med. 2011 May;123(3):133-43. doi: 10.3810/pgm.2011.05.2291.
10
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.慢性肾脏病和透析终末期肾病患者的抗糖尿病药物：代谢和临床实践。
Curr Drug Metab. 2011 Jan;12(1):57-69. doi: 10.2174/138920011794520053.